You are here

Boston Children’s Hospital

300 Longwood Avenue
Boston, MA 02115
United States

 

Alveolar rhabdomyosarcoma is an aggressive childhood cancer, and many children with this disease carry a mutation that combines two different proteins, PAX3 and FOXO1, into one protein, PAX3-FOXO1. This creates a protein with new function, causing changes in gene expression that leads to cancer. Children with this mutation face poor outcomes. This fusion protein is highly dynamic and samples many different structures, too many to reasonably count in fact. This makes the protein hard to drug because we traditionally target stably folded regions of proteins.

Boston Children’s Hospital

Mentor Name: Leonard Zon

Boston Children’s Hospital

In recent years, researchers have found ways to artificially reprogram our own immune system so that it recognizes specific markers and fights tumor cells. Unfortunately, certain pediatric cancers, such as acute myeloid leukemia (a type of blood cancer), are difficult to treat because the cells that make up the tumor either have the same targets as healthy cells, causing undesired effects on normal organs, or are resistant to elimination by the immune system.

Boston Children’s Hospital
Boston Children’s Hospital
Boston Children’s Hospital

Background

The LIN28 family of RNA binding proteins are known drivers of many pediatric cancers. These proteins function by blocking the function of the let-7 family of microRNAs, which exert tumor suppressive effects. To date, despite the panoply of childhood tumors driven by LIN28, efforts to target this protein in pediatric cancer are lacking.

Pages